Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (161-170 of 193) with videos related to

Pageof 20
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.
Journal of Medicinal Chemistry|July 18, 2020
Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source AntimalarialsEdwin G Tse, Sevan D Houston, Craig M Williams, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2007
The time to move cytochrome p450 induction into mainstream pharmacology is long overdueDennis A Smith, Maurice Dickins, Odette A Fahmi, et al.
Journal of Medicinal Chemistry|September 28, 2023
The Importance of Tracking "Missing" Metabolites: How and Why?Shuai Wang, T Eric Ballard, Lisa J Christopher, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 26, 2025
Applications of contemporary tools to measure plasma protein binding of targeted protein degradersMark Niosi, Sam Zhang, Woodrow Burchett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 29, 2021
Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and InhibitionEric Gonzalez, Sankalp Jain, Pranav Shah, et al.
Journal of Pharmaceutical Sciences|April 17, 2013
Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in humanAarti Sawant-Basak, Karen J Coffman, Gregory S Walker, et al.
Clinical Pharmacology and Therapeutics|June 9, 2022
Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug DevelopmentRavi Shankar P Singh, Gregory S Walker, Eugene P Kadar, et al.
Journal of Medicinal Chemistry|February 22, 2008
2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonistsYuhpyng L Chen, R Scott Obach, John Braselton, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Pageof 20

Showing results (161-170 of 193) with videos related to

Sort By:
Pageof 20
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.
Journal of Medicinal Chemistry|July 18, 2020
Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source AntimalarialsEdwin G Tse, Sevan D Houston, Craig M Williams, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 27, 2007
The time to move cytochrome p450 induction into mainstream pharmacology is long overdueDennis A Smith, Maurice Dickins, Odette A Fahmi, et al.
Journal of Medicinal Chemistry|September 28, 2023
The Importance of Tracking "Missing" Metabolites: How and Why?Shuai Wang, T Eric Ballard, Lisa J Christopher, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 26, 2025
Applications of contemporary tools to measure plasma protein binding of targeted protein degradersMark Niosi, Sam Zhang, Woodrow Burchett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 29, 2021
Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and InhibitionEric Gonzalez, Sankalp Jain, Pranav Shah, et al.
Journal of Pharmaceutical Sciences|April 17, 2013
Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in humanAarti Sawant-Basak, Karen J Coffman, Gregory S Walker, et al.
Clinical Pharmacology and Therapeutics|June 9, 2022
Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug DevelopmentRavi Shankar P Singh, Gregory S Walker, Eugene P Kadar, et al.
Journal of Medicinal Chemistry|February 22, 2008
2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonistsYuhpyng L Chen, R Scott Obach, John Braselton, et al.
Current Drug Metabolism|June 25, 2005
A comprehensive listing of bioactivation pathways of organic functional groupsAmit S Kalgutkar, Iain Gardner, R Scott Obach, et al.
Pageof 20